Rediscovering Chirality - Role of S-Metoprolol in Cardiovascular Disease Management.
Director and HOD Cardiology, Fortis Hospital, New Delhi.
Honarary Consultant and Diabetologist, Saifee Hospital, S.L. Raheja Hospital, Bhatia Hospital and Sir H.N. Hospital, Mumbai, Maharashtra.
Medical Services, Emcure Pharmaceuticals Ltd., Pune, Maharashtra.
- Published Article
The Journal of the Association of Physicians of India
- Publication Date
Jun 01, 2017
Chirality is a good way forward in providing a new drug molecule which is safe with lesser pharmacokinetic and pharmacodynamics variability, lesser side effects and more potent action. S-metoprolol is chirally pure form of racemate metoprolol and has lesser side effects, is safer in patients of COPD and Diabetes who also have hypertension and comparable responder rates at half the doses when compared to racemate.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/28782316